CMV-AsCpf1 AAV (Serotype 9)

CMV-AsCpf1 AAV (serotype 9) refers to an adeno-associated virus (AAV) vector engineered to express the AsCpf1 nuclease under the control of a cytomegalovirus (CMV) promoter. This vector system leverages the unique properties of the AAV vector and the AsCpf1 nuclease to provide a powerful system for gene editing applications. AAV serotype 9 has a high tropism for cardiac and skeletal muscle tissues and has been shown to penetrate the blood-brain barrier. This makes it particularly important for targeting organs that are difficult to reach with gene therapy vectors. In addition, AAV9 is highly regarded for its relatively low immunogenicity and ability to be expressed for long periods of time in humans, representing a promising avenue for therapeutic applications.

This vector system uses the CMV promoter, which is known for its efficient and ubiquitous expression in a variety of host cells. This ensures efficient expression of the AsCpf1 nuclease, facilitating precise gene editing tasks. AsCpf1, also known as Cpf1, belongs to the CRISPR-Cas nuclease family and is characterized by its ability to induce DNA double-strand breaks at specific target sites. It has many advantages over other nucleases such as Cas9, such as a smaller size (which is critical for packaging into AAV vectors) and the ability to make staggered cuts, which can improve precision and efficiency in certain applications.